Peter Blume-Jensen, M.D., Ph.D. is Founder, President, and CEO of Acrivon Therapeutics, Inc. He has extensive experience in oncology R&D and oncogenic kinase signaling. From 2001 to 2008, Peter was Department Head at Serono, US and later at Merck & Co, Inc. where he established and led integrated oncology drug programs into the clinic. From 2008 to 2010, he was Vice President, Ext. Sci. Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, Inc. He co-led the scientific due diligence and M&A resulting in the acquisition of Plexxikon. From 2010-2014 he was CSO for Metamark Genetics where he built R&D and a novel, scripted proteomics tissue imaging platform. Here he led 4 clinical studies culminating with the blinded validation and launch of ProMark®, an outcome-predictive prostate cancer biopsy test included under NCCN guidelines and coverage. From 2014 till 2018 Peter was CSO for XTuit Pharmaceuticals where he established a novel prodrug platform in collaboration with Dr. Jeremiah Johnson, MIT, now continued at Window Therapeutics. Peter is the inventor of the AP3 platform and the OncoSignature patient selection method.
Peter serves on the SAB for several private biotech companies and academic institutions. His review “Oncogenic Kinase Signaling (Nature, 2001) is a citation classic in the field of clinical medicine. He received his M.D. from Copenhagen University Medical School, Denmark, his Ph.D. from The Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.